310 related articles for article (PubMed ID: 36281357)
1. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
Wang Z; Yao J; Dong T; Niu X
J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
3. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
Ma C; Gu Z; Yang Y
J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
[TBL] [Abstract][Full Text] [Related]
4. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction.
Li L; Cai Q; Wu Z; Li X; Zhou W; Lu L; Yi B; Chang R; Zhang H; Cheng Y; Zhang C; Zhang J
Sci Rep; 2023 Feb; 13(1):2455. PubMed ID: 36774446
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
8. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
Wang Y; Xiao X; Li Y
Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
[TBL] [Abstract][Full Text] [Related]
9. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
10. Identification and integration analysis of a novel prognostic signature associated with cuproptosis-related ferroptosis genes and relevant lncRNA regulatory axis in lung adenocarcinoma.
Wang T; Jiang X; Lu Y; Ruan Y; Wang J
Aging (Albany NY); 2023 Mar; 15(5):1543-1563. PubMed ID: 36881404
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
Xu Q; Liu T; Wang J
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
Tu H; Zhang Q; Xue L; Bao J
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-related gene signatures for predicting prognosis of lung adenocarcinoma.
Ye W; Huang Y; Li X
Medicine (Baltimore); 2022 Oct; 101(40):e30446. PubMed ID: 36221373
[TBL] [Abstract][Full Text] [Related]
16. Identification of a cuproptosis-related lncRNA prognostic signature in lung adenocarcinoma.
Chen R; Luo H; Chen Q; Wang C
Clin Transl Oncol; 2023 Jun; 25(6):1617-1628. PubMed ID: 36609650
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and personalized treatment prediction in lung adenocarcinoma: An
Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z
Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011
[No Abstract] [Full Text] [Related]
18. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
19. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
20. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]